ArticleScientific reports2026
Predicting genetic evolution of viruses to identify suitable vaccines using artificial intelligence.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rethinking non-human primate models for emerging viral infections after COVID-19.Laboratory animal research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The evolution of the viruses is rapidly becoming a global challenge to the creation of vaccines since the new variants are often capable of escaping the immune system and decreasing the vaccine efficacy. The traditional methods of genomic epidemiology rely on the retrospective phylogenetic analysis, which can elucidate the previous mutations, but cannot predict the evolutionary trends in the future. In order to address these disadvantages, a new Refined Deep Evolutionary Learning Framework (R-DELF) is proposed that combines the genomic, structural, and temporal intelligence in predicting proactive viral mutations and assessing vaccine suitability. The methodology uses an ESM-2 Transformer that extracts structure-aware embeddings, merged with dual-attention Graph Neural Networks (GNNs) which learn phylogenetic and structural dependencies. Evolutionary learning maximiser improves adaptation modelling and an Explainable AI layer, which offers interpretability based on residue-level attribution. Tests indicate that experimentally it achieves 99.2% accuracy, 97.92% precision, 98.89% recall and 99.4% F1, which is higher than the current AI-based virology models. It is implemented in Python and with the help of TensorFlow and genomic and protein data obtained via Kaggle. The framework allows predicting the high-risk mutations in advance, facilitates the production of vaccines on time, and increases the preparedness to pandemics by making intelligent, data-driven predictions of viral evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.